Tweets
Links:
Dr. John Cush @RheumNow ( View Tweet )
13 minutes 21 seconds ago
CAR T Gets the Spotlight. Are We Missing the B Cells That Matter?
CAR T is having its moment in rheumatology. But William Robinson’s presentation at ACR Convergence 2026 raised a question I find even more compelling: are we failing to eliminate the right B cells with therapies https://t.co/uta77oaayo
Dr. John Cush @RheumNow ( View Tweet )
32 minutes 3 seconds ago
Falls Hide in Plain Sight in Rheumatic Disease
A patient with arthritis pitches forward onto her knees and wrists while bending to grab something. Another time she tries to get up and lands on the bed. Another time she uses a chair to lower herself to the floor.
By the World https://t.co/kmmaRxhII0
Dr. John Cush @RheumNow ( View Tweet )
1 hour 31 minutes ago
Which ACR 2026 findings will you take back to clinic?
Join us Monday, November 16 through Friday, November 20 for RheumNow’s ACR 2026 Topic Panel Recaps. Each panel streams live at 7 PM ET / 6 PM CT / 4 PM PT.
Watch live on X, YouTube, LinkedIn, or Facebook. All five panels https://t.co/RbWjwNgljY
Dr. John Cush @RheumNow ( View Tweet )
2 hours ago
Is It Still Inflammation?
A 34 year old female has axSpA. Her CRP is 3, her MRI is quiet, and her BASDAI is 7. She has tried two biologics and is asking about a third. Before we write that prescription, #ACR26 challenges us to ask a different question: is it still inflammation? https://t.co/fLGgnBCXS8
Dr. John Cush @RheumNow ( View Tweet )
3 hours 2 minutes ago
Beyond HLA-B27: Anti-14-3-3eta Autoantibodies as a Candidate Marker in axSpA
14-3-3 proteins are a conserved family of seven isoforms with diverse cellular functions, found predominantly intracellularly. The 14-3-3eta isoform has been studied as a proinflammatory mediator in RA https://t.co/tErmfDBy1r
Dr. John Cush @RheumNow ( View Tweet )
6 hours 29 minutes ago
IgG4-RD in 3 Talks: Shorter Steroids, Earlier B-Cell Therapy
IgG4-related disease now has two phase 3 trials and its first dedicated treatment guidelines. Glucocorticoids remain the weak point.
https://t.co/pWu1eoiMVG https://t.co/k9aFvYhQSB
Dr. John Cush @RheumNow ( View Tweet )
20 hours 31 minutes ago
One Diagnosis, Different Diseases: Is TLR7/8 Inhibition the Future of Lupus Treatment?
We call it systemic lupus erythematosus (SLE), but are we really treating one disease? Increasingly, I wonder whether grouping biologically distinct patients under one diagnosis is limiting https://t.co/EkudaG7YiY
Dr. John Cush @RheumNow ( View Tweet )
22 hours 32 minutes ago
Pre-RA: Antibodies Sort the Risk, Ultrasound Erosions Flag Severity
Three ACR 2026 abstracts from the Leeds CCP cohort tested how to triage anti-CCP positive individuals with musculoskeletal symptoms. Serology and a few clinical items carried the prediction, while ultrasound https://t.co/91HG7xPS3o
Dr. John Cush @RheumNow ( View Tweet )
1 day 20 hours ago
Efgartigimod: A New Mechanism for Myositis?
Abstracts come and go, but new trials and new mechanisms stay with us for the long haul. One of the more interesting new mechanisms is the FcRn drugs, and at ACR Convergence 2026 we got to see positive results from the Phase 3 ALKIVIA https://t.co/cCgItPQSPS
Dr. John Cush @RheumNow ( View Tweet )
1 day 22 hours ago
“Age old” biomarkers in ILD and pulmonary fibrosis
At #ACR26, there was a poster on senescence being increased in SARD-ILD (systemic autoimmune rheumatic disease – interstitial lung disease) including fibrotic (progressive pulmonary fibrosis), showing epithelial remodeling from https://t.co/cNxgqJIH8T
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
AI vs Rheumatologist? The Better Answer May Be Both
Can artificial intelligence answer patients’ rheumatology questions as well as a rheumatologist? Abstract 2965 at #ACR26 suggests the answer may be yes, but also highlights why physician oversight still matters. https://t.co/RNbCUFjMQo
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
Why Did the Last Drug Fail?
When a patient fails a drug, we tend to consider what will be the next drug. Most of our clinics have patients on their second or third advanced therapy. Drug failure has become more common, not less. A question that we too rarely write in the notes https://t.co/r5mQjI79iQ
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
Looking for RA-ILD: 9 Clinical Clues from ANCHOR-RA
Which of our RA patients will develop RA-ILD, and how can we better identify these patients? In abstract #2884 at #ACR26 , Dr. Jeffrey Sparks presented findings from ANCHOR-RA trial, a large prospective cross-sectional study https://t.co/P96KAcPmWt
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
It was a beautiful Year in Preview from @AlexisOgdie - here's a summary of her take on what might be to come in rheumatology in the year ahead
#ACR26 @RheumNow https://t.co/DneNoUkc7u https://t.co/jlAdwZYAQI
Links:
David Liew @drdavidliew ( View Tweet )
2 days ago
